Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
Become a Member | Sign in
Home>News>This Article

G3 Completes GLOBAL Study Patient Enrollment

Published: Thursday, February 13, 2014
Last Updated: Monday, February 17, 2014
Bookmark and Share
Pilot data of single largest prospective pan-omic study to identify key biomarkers and central therapeutic targets for cardiovascular diseases.

Global Genomics Group (G3) announce that it has completed enrollment of the 5,000-patient discovery cohort of its GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) clinical study. Pilot data for the first cohort of patients are expected later this year.

The GLOBAL study, designed to identify disease-related pathways, new drug targets and biomarkers for cardiovascular diseases such as atherosclerosis, enrolled 5,000 patients in the discovery group, with approximately 2,500 patients in the control group and approximately 2,500 patients in the case group. Precision phenotyping is conducted with cardiovascular computed tomography (CT), including calcium scoring and CT angiography, an advanced, non-invasive imaging technology. A pan-omic analysis that includes whole genome sequencing, whole genome methylation, whole transcriptome sequencing, unbiased proteomics, metabolomics and lipidomics, will be conducted for every patient. The data will be analyzed with systems biology driven bioinformatics.

"The strong interest and support from the medical community has allowed us to rapidly enroll patients at many of the top centers worldwide, and we are well ahead of our original schedule," said Bradley Brown, co-founder and vice president of clinical affairs of G3. "This is an important milestone for G3 as well as for our collaborating researchers and participating patients. The GLOBAL study will allow us to gain important insights about the development of cardiovascular disease and to identify new disease biomarkers and therapeutic targets. We anticipate that the pilot data set will be available later this year."

The GLOBAL study is enrolling patients at 48 institutions in 9 countries and across three continents. The investigators anticipate enrolling an additional 2,000 patients in the validation cohort, with approximately 1,000 patients in the disease group and 1,000 in the control group.

Stephen Bloom, M.D., of Midwest Heart & Vascular Specialists, Kansas City, Mo., a principal investigator of the study, said, "Cardiovascular disease remains the leading cause of death worldwide, and the biological pathways leading to atherosclerosis — the primary reason for heart attacks and stroke — remain largely unknown. The GLOBAL study is the most ambitious study ever undertaken to investigate the root cause of this complex disease and may not only provide us with new biomarkers and drug targets, but it will also provide us with a platform for early screening, continued monitoring of risk, prevention and early intervention."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

G3, Caprion Partner on Global Cardiovascular Disease Biomarker Study
Caprion to identify blood-based protein markers for study.
Wednesday, February 26, 2014
Scientific News
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Circadian Clock Controls Insulin and Blood Sugar in Pancreas
Map of thousands of genes suggests new therapeutic targets for diabetes.
Cellular Stress Process Identified in Cardiovascular Disease
Combining the investigative tools of genetics, transcriptomics, epigenetics and metabolomics, a Duke Medicine research team has identified a new molecular pathway involved in heart attacks and death from heart disease.
Predicting Adverse Drug Reactions with Higher Confidence
A new integrated computational method helps predicting adverse drug reaction—which are often lethal—more reliably than with traditional computing methods.
A New Way to Starve Lung Cancer?
Metabolic alterations in lung cancer may open new avenues for treating the disease.
Evidence of How Incurable Cancer Develops
Researchers in the West Midlands have made a breakthrough in explaining how an incurable type of blood cancer develops from an often symptomless prior blood disorder.
Building a Better Liposome
Computational models suggest new design for nanoparticles used in targeted drug delivery.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos